Abstract
Purpose: To study the influence of Qianliexin capsule on quality of life, NIH-CPS Index, and 5-item version of the 15-item International Index of Erectile Function (IIEF-5) scores in patients with prostatitis complicated with erectile dysfunction (ED).Methods: Patients with prostatitis complicated with ED (128) who were treated from November 2015 to December 2017 participated in this study. The patients were assigned to two groups (64 per group) according to the treatment given: study group which was given routine treatment plus Qianliexin capsule, and control group which received routine treatment only. Clinical effectiveness, adverse reactions, Quality of Life-Bref (QOL-BREF) scores, etc, of the two groups were determined.Results: The QOL-BREF score of the study group was significantly higher than that of the control group (p < 0.05). While NIH-CPSI scores were significantly decreased in both groups, the decrease in the study group was lower (p < 0.05). In contrast, IIEF-5 score significantly increased in both groups, but the increase in the study group was higher than in control (p < 0.05).Conclusion: Qianliexin capsule is an effective and reasonably safely drug for enhancing the quality of life, NIH-CPSI and IIEF-5 scores, as well as the lecithin bodies in prostatitis patients with ED.Keywords: Qianliexin capsule, Prostatitis, Erectile dysfunction NIH-CPSI score, IIEF-5 score
Highlights
Prostatitis is a common disease in the urinary surgery department
It is believed that Qianliexin capsule, as a bloodregulating recipe, can activate blood to resolve stasis, removing heat and dampness, all of which are beneficial to the recovery of prostatitis patients with erectile dysfunction (ED) [8]
The present study investigated the effect of Qianliexin capsule treatment on QOL-BREF, NIH-CPSI and IIEF-5 of prostatitis patients with ED
Summary
The present study investigated the effect of Qianliexin capsule treatment on QOL-BREF, NIH-CPSI and IIEF-5 of prostatitis patients with ED. Patients in the control group were within the age range of 21 - 59 years (mean age = 33.7 years), with disease course of 5 to 59 months. If the symptoms of prostatitis completely disappeared and IIEF-5 score was over 22 points, recovery was implied; effective referred to 25 – 50 % decreases in IIEF-5 score, while NIH-CPSI less than 25 % and IEF-5 score below 25 % meant ineffective. After 2 months of treatment, questionnaire methods and QOL-BREF were used to assess psychological health and life quality of patients in both groups. Independent sample t-test was used for comparing NIH-CPSI, IIEF-5 and QOL-BREF scores, as well as WBC, lecithin body number, and IFN-γ and IL-8 levels in prostatic fluid. Values of p < 0.05 were considered statistically significant
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
